
Bicyclomycin benzoate
CAS No. 37134-40-0
Bicyclomycin benzoate ( FR2054 )
产品货号. M14280 CAS No. 37134-40-0
一种广谱抗生素,对革兰氏阴性菌和革兰氏阳性菌具有活性。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
50MG | ¥7197 | 有现货 |
![]() ![]() |
100MG | 获取报价 | 有现货 |
![]() ![]() |
200MG | 获取报价 | 有现货 |
![]() ![]() |
500MG | 获取报价 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称Bicyclomycin benzoate
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述一种广谱抗生素,对革兰氏阴性菌和革兰氏阳性菌具有活性。
-
产品描述A broad spectrum antibiotic active against Gram-negative bacteria and the Gram-positive bacterium; selectively inhibits transcription termination factor Rho, a RecA-type ATPase in E coli.
-
体外实验The primary action of bicyclomycin is due to interference with the biosynthesis of lipoprotein and its assembly to peptidoglycan in the cell envelope of E. coli. At the lethal level, bicyclomycin is shown to inhibit the synthesis of RNA and protein in the growing cells of E. coli 15 THU. Bicyclomycin targets the rho transcription termination factor in Escherichia coli. Bicyclomycin is a modest rho inhibitor, can disrupt the rho molecular machinery thereby leading to a catastrophic effect caused by the untimely overproduction of proteins not normally expressed constitutively, thus leading to a toxic effect on the cells. The inhibition of rho poly(C)-stimulated hydrolysis of ATP by bicyclomycin has been found to proceed by a non-competitive, reversible pathway with respect to ATP (Ki=20 μM).
-
体内实验Bicyclomycin has low excretion rate after a single intramuscular dose of 50 mg/kg in rats. Bicyclomycin is well distributed in various tissues, and the highest concentration is observed in the kidney at 100 mg/kg.
-
同义词FR2054
-
通路GPCR/G Protein
-
靶点Antibacterial
-
受体Antibacterial
-
研究领域——
-
适应症——
化学信息
-
CAS Number37134-40-0
-
分子量406.38658
-
分子式C19H22N2O8
-
纯度>98% (HPLC)
-
溶解度DMSO
-
SMILESCC(COC(=O)C1=CC=CC=C1)(C(C23C(=O)NC(C(=C)CCO2)(C(=O)N3)O)O)O
-
化学全称Bicyclomycin, 3'-benzoate
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Tanaka N, et al. J Antibiot (Tokyo). 1976 Feb;29(2):155-68.
2. Kohn H, et al. Curr Drug Targets Infect Disord. 2005 Sep;5(3):273-95.
3. Park HG, et al. Arch Biochem Biophys. 1995 Nov 10;323(2):447-54.